New research shows that some cancer drugs have the potential to treat Alzheimer's disease

In a new study, researchers from research institutions such as the National Institute on Aging (NIA) found that existing and emerging cancer drugs may be Therapies for the population to conduct clinical trials

These authors found changes in brain proteins associated with APOE4 genetic risk variants in young post-mortem study participants (average age of death was 39), and correlated these changes with Alzheimer’s disease patients and non-Alzheimer’s disease The changes in the autopsy brain of patients (average age at death of 89 years) were compared

This analysis includes brain samples from the Baltimore Longitudinal Study of Aging, the Religious Orders Study, and other NIA-funded research

Their results showed that an experimental drug for the treatment of liver cancer and Dasatinib, which is approved for chronic myelogenous leukemia, act on some of the proteins related to Alzheimer’s disease, indicating that they may be Potential drugs for the treatment of Alzheimer's disease

Identify early AD proteome characteristics

Picture from Science Advances, 2021, doi:10.

These findings provide evidence for another recent study, demonstrating the value of this data-driven approach in drug reuse research

Note: The original text has been deleted

Reference materials:

Jackson A.